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Introduction: Human papillomavirus (HPV) induce many cancer conditions and cause cervical cancer, second in
frequency of malignant disease in women.
The aim was to develop biomarker panel for HPV-induced cervical precancerous diseases in patients infected with
herpes simplex virus (HSV).
Material and methods: The study involved 71 women with cervical precancerous diseases (mean age 26 ± 5 years)
revealed by colposcopic, cytomorphological, and ultrasound signs which were assessed according to the following: first
group, 44 patients infected with HPV; second group, 27 HPV-negative patients; and third group, 30 healthy patients
(controls). In cervical specimen, we identified HPV DNA of different oncogenic risk types by polymerase chain reaction
(PCR). Enzyme-linked immunosorbent assay (ELISA) kits (JSC SPC ‘DiaprofMed’) were used for detecting antibodies to
HSV1 and/or HSV2 and for determining the avidity index. The production of pro-inflammatory cytokines, interferon-γ
(IFN-γ), IFN-α, TNF-α, and interleukin-1β (IL-1β), and anti-inflammatory cytokines, IL-4, IL-10, and transforming growth
factor-β1 (TGF-β1), were studied by ELISA.
Results: In HPV-induced cervix precancerous diseases, we identified low-avidity IgG antibodies to HSV serum of 20
patients; in the serum of 17 patients, we identified average-avidity antibodies, and high-avidity antibodies were found
in 2 patients only. In 14 HPV-negative patients, we found low-avidity IgG antibodies to HSV; in 10 patients, medium
avidity. Patients with low-avidity IgG antibodies to herpes virus showed high and medium oncogenic risk HPV types
and a decrease of IFN-γ compared to patients with medium-avidity IgG antibodies. Production of IFN-γ was suppressed
also in HPV-negative patients with cervical precancers, but we found low- and medium-avidity IgG antibodies to herpes
virus. In patients with low-avidity antibodies, we observed increased level of IL-10. Level of IFN-α, IL-1β, IL-2, and IL-4
did not change in patients of all groups, but TGF-β1 increased.
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Conclusions: In HPV-positive patients, those with low-avidity IgG antibodies to HSV had immunosuppression,
confirmed by increased TGF-β1 and violation of IFN-γ production. Therefore, in pro- and anti-inflammatory cytokines
and IgG antibodies to HSV, their avidity is an important diagnostic biomarker of HPV-induced precancerous cervical
diseases. Low-avidity IgG antibodies may be an indication for treatment with immunomodulators and antiviral drugs.
Keywords: Predictive, Preventive, Personalized medicine, Pro- and anti-inflammatory cytokines, Papillomavirus, Herpes
simplex virus infections, Cervical precancerous lesions, HPV-induced cervical precancerous diseases, Pro- and
anti-inflammatory cytokines, Antibodies, Avidity, Immunomodulators, Ultrasonography, Biomarker panelOverview
Predictive, preventive and personalized medicine in
cervical cancer
Women health and gender-related pathology is among the
priorities for predictive, preventive, personalized medicine
(PPPM) [1-4] - an innovative approach towards gynecology
cancer prevention that aims at detection of pre-malignant
stages for novel integrative cancer management including
development predictive schemes followed by tailored pre-
vention with implementation of personalized treatment
strategies [3]. Cancer of the cervix (cervical cancer, CC) is
the second most common cancer in women worldwide, with
about 500,000 new cases and 250,000 deaths each year [5].
Human papillomavirus (HPV), which induces a wide
range of diseases and precancerous tumor genesis, is the
most important risk factor for cervical cancer. The inter-
action of oncoproteins E6 and E7 of high oncogenic risk
with intracellular factors is a key stage for induction of
malignant transformation. These factors play an import-
ant role in the regulation of growth, differentiation and
apoptosis, which may lead to instability of the genome
and malignant transformation [6-9].
The risk co-factors of HPV-induced cancer are as follows:
 Patients infected by other sexually transmitted
pathogens, especially viruses like herpes simplex
virus (HSV) [2];
 The violation of a specific cellular immune response
[8-11] and production of Th1-type cytokines, etc.
[12-17];
 HPV type, especially in the case of cervical infection;
 Frequent multiple full-term pregnancies and birth
giving before 16 years;
 Congenital and/or acquired immunosuppression;
 Patients infected with HSV-2;
 Use of steroids (dexamethasone, progesterone and
estrogen and corticosteroids), oral contraceptives;
 Genetic factors - polymorphism of the E2 protein gene
of HPV and molecules of the major histocompatibility
complex (MHC), interferon-γ (IFN-γ), tumor necrosis
factor-α (TNF-α) and interleukin-1β (IL-1β);
 Smoking, lack of antioxidants in the body or folic acid
due to low socio-economic standard of living, etc.It was noted that E6 and E7 oncoproteins of high onco-
genic risk HPV have immunosuppressive activity directed
primarily to the inhibition of gene expression of IFN and
IFN-induced genes, as well as decrease in the production
of IL-18, which directly regulates γ-interferonogenesis.
This in turn affects the balance of cytokines Th1 and Th2
type and thus determines the main path of development
of the immune response - either by Th1 or by Th2 type
[9,18,19]. The carcinogenesis in HPV infection also in-
volves Th3-type cytokine, including anti-inflammatory
transforming growth factor-β (TGF-β) [20,21].
The role of pro-inflammatory cytokines is ambiguous,
which can affect both the formation of the body’s immune
defence in the HPV [9,22-24] and enhance the growth of
transformed cells, as shown in vitro [18]. We have previ-
ously found that in cervical cancer patients with HPV with
severe cervical intraepithelial neoplasia (CIN), the produc-
tion of IFN-γ and IFN-α was suppressed and the production
of pro-inflammatory cytokines and TGF-β increased [15].
Possibly, an imbalance of pro- and anti-inflammatory pro-
duction of cytokine may be a risk factor for HPV-induced
malignancies and underlie cervical cancer relapse in HPVI.
The issue of the role of HSV-1 and HSV-2 as co-factors
of HPV-induced carcinogenesis was debated for a long time
since 1982 [6]. HSV can increase the replication of high
oncogenic risk HPV and its integration into the genome of
the host cell [19], enhancing the expression of oncogenes
E6 and E7, that is considered a relevant prerequisite for
HPV-induced malignant transformation [25,26].
The results of epidemiological studies [27,28] also sup-
port the importance of role of HSV as a possible co-factor
of HPV-induced cervical cancer. However, it was concluded
that infection with HSV is not an obligatory factor for
maintaining the transformed phenotype of cells in HPV-
induced cancers [29,30]. In favor of co-factor mechanism of
HSV-2 supported with the fact that the HPV-induced cer-
vical adenocarcinoma, HPV DNA was not integrated into
the genome of transformed cells transport in any case [29].
We have previously reported [31] that in the serum of
most patients with HPV-induced cervical dysplasia,
class G antibodies to HSV-1 and/or HSV-2 were found,
which had mostly low or medium avidity index, which
indicates on the final stage of primary infection, and the
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low-avidity antibodies to HSV-1 and/or HSV-2, CIN
was diagnosed in major cases than in patients with anti-
bodies with medium avidity to these viruses. However,
it remains still unknown how HSV can function as a co-
factor for HPV-induced CC.
The aim was to assess the production of pro- and anti-
inflammatory cytokines in HPV-induced cervical precan-
cerous diseases in patients infected with HSV-1 and/or
HSV-2 in serum IgG, identified with varying degrees of
avidity, specific to these HSV.Figure 2 Cytology of cervical epithelium, HPV-induced CIN II.
Binuclear koilocytes with signs of atypia. Painted by Pappenheim
(×100 magnification).Methods
Patient’s inclusion and sample collection
The study involved 71 women with cervical precancer-
ous diseases (mean age 26 ± 5 years). Human papilloma-
virus infection and cervical precancerous diseases were
diagnosed on the basis of colposcopic [32] and cytomor-
phological [33,34] and ultrasound (US) data. The survey
was conducted at the Department of Obstetrics and
Gynecology, Odessa National University (Ukraine).
All patients underwent general clinical examination,
which included clinical and biochemical blood tests,
blood tests for HIV, RW, HBS-Ag and HCV-Ag, clinical
urine tests, ECG, ultrasound, chest X-rays and a study of
vaginal biotope (microflora), according to the protocols
of the Ministry of Health of Ukraine.
According to the nature of the pathological process in
cervix, we formed the following groups of patients with
cervix precancerous diseases: (1) 44 patients identified
HPV DNA in cervical specimen with colposcopic, cyto-
morphological (Figures 1, 2, 3 and 4), molecular and ultra-
sound signs of cervical precancerous diseases; (2) 27
patients, whom HPV DNA in cervical specimen were not
identified but showing colposcopic, cytomorphologicalFigure 1 Cytology of cervical epithelium, HPV-induced CIN I.
Binuclear koilocytes with enlightenment zone around the nucleus,
which arises from the cytopathic action of the virus, with a dense
basophilic cytoplasm in a state of vacuole dystrophy. Painted by
Pappenheim (×100 magnification).and ultrasound signs of cervical precancerous diseases and
(3) the control group included 30 healthy women.
The patients were distributed into the groups with non-
significant difference among groups as regards to age.
The design of the study was prospective, non-randomized.
From the patients and clinically healthy women, non-
heparinized peripheral blood (20 ml) was taken to obtain
the serum.
HPV typing
DNA HPV detected by polymerase chain reaction (PCR)
in cervical specimen. The HPV DNA of different onco-
genic types: high (HPV 16, 18, 45, 56), medium (HPV 31,
33, 35, 51, 52, 58) and low (HPV 6, 11, 42, 43, 44).
ELISA for detecting antibodies to HSV-1 and/or HSV-2 and
determination of avidity index
For screening the sera for IgG for presence of HSV, we
used the test system ‘DIA-HSV-1/-2-IgG’, constructed
in the form of indirect solid phase enzyme immunoassay
(ELISA). The solid phase polystyrene plates PolySorpFigure 3 Cytology of cervical epithelium, HPV induced CIN II.
Squamous cells with enlarged nucleus. Painted by Pappenheim
(×100 magnification).
Figure 4 Cytological examination of material cervix, HPV-
induced CIN III. (A) Binuclear koilocytes. (B) Multinucleated cells
with signs of atypia. Painted by Pappenheim (×100 magnification).
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of recombinant proteins gG1 and 2 gG (JSC SPC
‘DiaprofMed’, Ukraine). Murine monoclonal antibodies to
human IgG labelled with horseradish peroxidase were
used as a conjugate. TMB reaction, diluted in citrate buffer
containing hydrogen peroxide, was used as a developer.
Differential diagnosis for HSV-1 and HSV-2 was per-
formed using kits manufactured in the same format as
above. However, in the immunosorbent, only the recom-
binant proteins gG1 or gG2 were used respectively. Based
on the last test, the system was designed such that it en-
ables not only to detect IgG to HSV but also to determine
the degree of avidity.
The avidity index was calculated as the percentage of
absorbance obtained in the test sample in the presence
of a dissociating agent; the absorbance was obtained in
its analysis as usual regimen. Thus, if avidity index was
less than 30%, we supposed that serum contains low-
avidity antibodies, in the range of 30% to 60%, it con-
tains medium-avidity antibodies, and if more than 60%,
high avidity. The setting reaction was conductedaccording to the manufacturer’s instructions for these
kits (JSC SPC ‘DiaprofMed’).
Cytokine analysis
The production of pro-inflammatory cytokines, IFN-γ,
IFN-α, TNF-α, IL-1β and anti-inflammatory cytokines,
IL-4, IL-10, TGF-β1, in determining the levels of these
cytokines in serum of patients was studied by ELISA.
To determine the serum TGF-β1, we used test produc-
tion system User’s Manual (DRG Instruments GmbH,
Germany). The levels of IFN-γ, IFN-α, TNF-α, IL-1β, IL-4
and IL-10 in serum were determined using appropriate
ELISA test kits of Vector-Best (Russian Federation). Set-
ting ELISA was performed according to the manufac-
turer’s instructions specified test systems.
Statistical analysis
These data were processed by a computer program
STATISTICA. The null hypothesis for the control and
experimental groups tested using non-parametric
Kolmorogov-Smirnov test. Data was presented as M ±
SEM. Some experimental results are presented as me-
dian and interquartile range MAE (LQ −UQ), where
Me is the median, LQ and UQ are the lower and upper
quartiles, respectively. The significance level for all tests
was 5% (p = 0.05).
The written informed consent for research was obtained
from all patients. The medical ethics commissions of the
Odessa National Medical University approved the study.
Study limitation
The study was non-randomized, non-blinded. We are
aware of small numbers made; it was difficult to exclude
selection bias and information bias: the patients were mo-
tivated to participate in these studies because they had the
access to their diagnostic profile that determined a tactic
of personalized treatment using immunomodulators and
antiviral drugs. Due to technological and financial limita-
tions, we were not able to evaluate the extensive panel of
the existing biomarkers to suggest reliable predictive pro-
gram. Serum and imaging (US) biomarkers were assessed
on small group of patients. For this reason, biomarker spe-
cificity/sensitivity was not evaluated as well as the mea-
surements of individual outcomes were not sufficiently
assessed according to the findings of the study.
Results
Groups of patients and characterization of the
pathological process
In HPV-induced cervical precancerous diseases, we identi-
fied IgG antibodies to HSV-1 and/or HSV-2 with low avid-
ity in serum of 20 patients; in serum of 17 patients, we
identified IgG antibodies to HSV-1 and/or HSV-2 with
average avidity, and high-avidity IgG antibodies to these
Lazarenko et al. The EPMA Journal 2014, 5:1 Page 5 of 20
http://www.epmajournal.com/content/5/1/1HVS were found in serum of 2 patients only. Antibodies
to HSV-1 and/or HSV-2 were not found in serum of two
HPV-positive patients.
In the serum of 14 HPV-negative patients, we revealed
IgG antibodies to HSV-1 and/or HSV-2 with low avidity,
and serum of 11 patients in this group had IgG antibodies
to HSV-1 and/or HSV-2 with a medium avidity; high-
avidity IgG antibodies to these HVS were found in serum
of 1 patient only. Antibodies to HSV-1 and/or HSV-2 were
not found in the serum of two HPV-negative patients.
In HPV-induced cervical precancerous diseases, we de-
tected HPV of high oncogenic risk (HPV 16, 18, 45, 56),
medium (HPV 31, 33, 35, 51, 52, 58) and low (HPV 6, 11,
42, 43, 44) (Figure 5). Thus, in 13 of 20 patients (65.0%
cases) with low-avidity IgG antibodies to HSV-1 and/or
HSV-2, we identified high-risk HPV types (2 patients had
also medium risk HPV types). In six patients (30.0% cases)
with low-avidity IgG antibodies to HSV-1 and/or HSV-2,
medium-risk HPV types were identified. In one patient
only (5.0% cases) with low-avidity IgG antibodies to HSV-
1 and/or HSV-2, low-risk HPV types were identified.
In 10 of 17 patients (58.9% cases) with medium-avidity
antibodies to HSV-1 and/or HSV-2, high-risk HPV types
were identified (4 patients were also medium-risk HPV
types). In 3 patients (17.6% cases) with medium-avidity
antibodies to HSV-1 and/or HSV-2, medium-risk HPV
types were detected. Low-risk HPV types was identified in
four HPV-positive patients (23.5% cases) with low avidity
antibodies to HSV-1 and/or HSV-2.
Thus, high- and medium-risk HPV types were more
common in patients with low-avidity IgG antibodies toFigure 5 Frequency of HPV infection of high, medium, and low
oncogenic risk of patients with cervical precancerous diseases.
Precancer conditions of low- (A) and medium-avidity (B) IgG
antibodies to HSV-1 and/or HSV-2 in serum (data presented in %).HSV-1 and/or HSV-2 (95.0% of cases) than in patients
with medium-avidity IgG antibodies to HSV (76.5% of
cases) in serum.
Two patients with high-avidity antibodies to HSV were
infected with high-risk HPV types.
Production of pro-inflammatory cytokines
The study of production of pro-inflammatory cytokines
IFN-α, IFN-γ, IL-1β, IL-2, and TNF-α in patients with
cervical precancerous diseases with low or medium-
avidity serum IgG antibodies to HSV-1 and/or HSV-2 is
presented in Table 1.
We found that IFN-α and IL-1β, IL-2 and TNF-α
production at the system level was not changed in
HPV-positive and HPV-negative patients with cervical
precancerous diseases, who had low or medium-avidity
IgG antibodies in serum to HSV-1 and/or HSV-2.
Thus, in these patients, the serum levels of these cyto-
kines were similar to that of the control group (clinic-
ally healthy women).
However, serum level of IFN-γ significantly decreased
in HPV-positive patients with low-avidity IgG antibodies
to HSV-1 and/or HSV-2 comparing to controls as well
as HPV-positive patients with medium-avidity IgG anti-
bodies to HSV-1 and/or HSV-2. It should be noted that
serum level of IFN-γ decreased slightly in HPV-positive
patients with medium-avidity IgG antibodies to HSV-1
and/or HSV-2, but the difference compared with the
controls was not statistical.
Serum IFN-γ was also significantly lower in HPV-
negative patients with cervical precancerous diseases
with both low and medium-avidity IgG antibodies to
HSV-1 and/or HSV-2 than in controls.
These data suggest that production of IFN-γ was sup-
pressed in HPV-positive patients with low-avidity IgG
antibodies to HSV-1 and/or HSV-2 as well as in HPV-
negative patients with cervical precancerous conditions of
low or medium-avidity antibodies to these herpes virus.
However, there are no dependencies between the level of
serum IFN-α, IL-1β, IL-2 and IL-4 in the two groups of
patients in comparing the presence of serum with low-
and medium-avidity or IgG antibodies to HSV-1 and/or
HSV-2.
Production of anti-inflammatory cytokines
It is shown that the median serum IL-4 levels in HPV-
positive patients with cervical precancerous conditions
of low- or medium-avidity IgG antibodies to HSV-1
and/or HSV-2 was respectively 3.6 pg/ml (0 to 6.8) and
3.2 pg/ml (5 to 0.1). In the control median serum, IL-4
levels were 0.1 pg/ml (0 to 0.305). Although we observed
a trend towards increased IL-4 in the serum of patients
relative to controls, the difference between all these pa-
rameters was not statistical.
Table 1 Serum cytokine levels in patients with cervical precancerous diseases with low or medium-avidity IgG





The concentration of cytokines pg/ml (M ± SEM)
IFN-α IFN-γ IL-2 TNF-α IL-1β
Clinically healthy - 71.30 ± 32.51 32.50 ± 13.25 7.08 ± 0.98 8.10 ± 1.60 41.80 ± 4.51
HPV-positive patients Low avid 96.27 ± 61.91 11.12 ± 5.31*** 10.44 ± 6.21 10.60 ± 6.8 43.93 ± 20.86
Middle avid 109.07 ± 78.52 25.47 ± 19.6 6.87 ± 1.60 8.68 ± 5.40 44.64 ± 18.43
HPV-negative patients Low avid 79.10 ± 25.59 9.42 ± 4.47* 8.39 ± 1.79 9.56 ± 5.38 43.00 ± 17.32
Middle avid 63.14 ± 25.53 11.69 ± 8.12** 8.46 ± 1.94 5.38 ± 1.34 42.98 ± 5.45
*p < 0.05 compared with control; **p < 0.025 compared with control; ***p < 0.025 compared with patients with medium-avidity antibodies to HSV-1 and/or HSV-2.
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with low- or medium-avidity IgG antibodies to HSV-1
and/or HSV-2 was respectively 7.6 pg/ml (0.1 to 44.8) and
2.2 pg/ml (0 to 50.3). In the control median serum, IL-10
levels in serum was 11.2 pg/ml (2.5 to 36.9). The differ-
ence between all these parameters was also not statistically
significant.
There was no statistical difference between the levels of
IL-4 in the serum of HPV-negative patients with cervical
precancerous conditions of low- or medium-avidity IgG
antibodies to HSV and that in the control. The median
serum IL-4 levels in those patients with low- or medium-
avidity IgG antibodies to HSV-1 and/or HSV-2 was re-
spectively 1.8 pg/ml (0 to 16.0) and 1.0 pg/ml (0 to 6.4).
In HPV-negative patients with low- and medium-avidity
IgG antibodies to HSV, the median serum IL-4 levels were
respectively 253.8 pg/ml (62.1 to 533.9) and 31.0 pg/ml
(7.2 to 52. 1). The difference between these figures is sta-
tistically significant (p < 0.05). The level of serum IL-10 in
HPV-negative patients with low-avidity IgG antibodies to
HSV-1 and/or HSV-2 was also statistically higher than the
level of this cytokine in serum HPV-infected patients both
with low- and medium-avidity IgG antibodies to HSV-1
and/or HSV-2 as well as in the control (p < 0.05).
However, the contents of another anti-inflammatory
cytokine TGF-β1 in serum significantly increased in all
patients with the cervical precancerous conditions as
low- and medium-avidity IgG antibodies to HSV-1 and/
or HSV-2 compared with those in the control group
(p < 0.001) (Figure 6).
Thus, we found no correlation between the changes in
serum IL-4 and the presence of these two groups of pa-
tients compared with precancerous diseases with low- or
medium-avidity IgG antibodies to HSV-1 and/or HSV-2 in
serum. The level of serum IL-10 increased only in HPV-
negative patients with low-avidity IgG antibodies to HSV-
1 and/or HSV-2. However, the level of TGF-β significantly
increased in the serum of patients of all groups compared.
Imaging findings - potential ultrasound biomarkers
Histologic examination of the cervical specimen in the
first and second groups showed CIN grade I in 31 cases,CIN grade II in 28 and CIN grade III in 22 patients. We
have not registered specific differences between the first
(HPV-positive) and second (HPV-negative) groups.
In patients of both first and second groups, we registered
the changes of structure of the cervix on ultrasound as
follows: cervical canal thickening over 5 mm (28 patients,
39.4%); hydrocerix, fluid in cervical canal in ovulatory
phase (23 patients, 32.39%); nabothian cysts in cervix (30
patients, 42.3%); local stiff cervical lesions, fibrosis (hypere-
choic bands) in cervical tissue (29 patients, 40.8%); deform-
ation of structure, rough boundary between the mucosa
and muscle layer (27 patients, 38%); cervicosis, including
stiff areas on sonoelastography of hyperechoic inclusions
(fibrosis/petrifications) (25 patients, 35.2%); cervical canal
polyps (14 patients, 19.7%); increased vascularization in
endocervix (22 patients, 31%); extensive fibrosis (hypere-
choic bands) in cervical tissue (7 patients, 9.9%); cervical
solid nodules; stiff in sonoelastography (3 patients, 4.2%)
and increased vascularization in endocervix and stroma
(6 patients, 8.45%). At sonography, mean cervical length
before treatment was 26.7 ± 6.9 mm and 21.2 ± 4.5 in con-
trols (P > 0.05).
For all US symptoms inherent to severe and moderate
cervical dysplasia (CIN grade II, III) (Figure 7), we ob-
tained statistical significance comparing to control group
(P < 0.01); for mild cervical dysplasia (CIN grade I), data
were insignificant (P > 0.05) due to small number of patients.
Diagnostic evaluation of ultrasound for revealing cer-
vical dysplasia and staging was as follows: the sensitivity
was 97.18% (95% CI, 90.17% to 99.58%); specificity was
83.33% (95% CI, 65.27% to 94.30%); positive predictive
value was 93.24% (95% CI, 84.92% to 97.74%) and negative
predictive value was 92.59% (95% CI, 75.67% to 98.88%).
The ultrasound findings are presented on Figure 7; the
distribution of US biomarkers for CIN grades is pre-
sented on the Table 2.
Discussion
Today, it is known that in the development of HPV-
induced cervical dysplastic lesions, the key impact has a
specific cellular immune reactivity to HPV, especially the
Th1-type response of T helper cells, that develops by
Figure 7 Ultrasound scans of cervical dysplasia. (A) Mild cervical dysplasia. (B) Severe cervical dysplasia. (C) Sonoelastography reveals stiff
areas in severe dysplasia. (D) Cervical nodule. (E) Sonoelastography reveals stiff nodule in severe dysplasia.
Figure 6 Changing the amount of TGF-β1 in serum of patients with the cervical precancerous diseases. In cervical specimen of HPV DNA with
low- and medium-avidity and IgG antibodies to HSV-1 and/or HSV-2 (data are presented as M ± Std. Dev). 1, control group (clinically healthy women);
2, patients with low-avidity IgG antibodies to HSV-1 and/or HSV-2; 3, patients with medium-avidity IgG antibodies to HSV-1 and/or HSV-2.
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Table 2 The ultrasound biomarkers in patients of three groups
US sign Cervical dysplasia (n = 71) Controls (n = 30)
Mean cervical length, mm 24.8 ± 6.2 21.2 ± 4.5
Mild cervical dysplasia (CIN grade I, n = 31)
Cervical canal thickening over 5 mm 28 6
Hydrocerix - fluid of cervical canal is ovulatory phase 23 7
Nabothian cysts in cervix 30 14
Local stiff cervical lesions, fibrosis (hyperechoic bands) in cervical tissue 29 12
Moderate cervical dysplasia (CIN grade II, n = 28)
Deformation of structure, rough boundary between the mucosa and muscle layer 27 6
Cervicosis stiff in sonoelastography areas of hyperechoic inclusions (fibrosis/petrifications) 25 -
Cervical canal polyps 14 -
Increased vascularization in endocervix 22 5
Severe cervical dysplasia (CIN grade III, n = 18)
Extensive fibrosis (hyperechoic bands) in cervical tissue 7 -
Cervical solid nodules; stiff in sonoelastography 3 -
Increased vascularization in endocervix and stroma 6 -
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lar, pro- and anti-inflammatory cytokines [9,14,35,36]. This
is confirmed by the fact that patients with immunodeficiency
states with suppressed cellular immunity, such as AIDS, are
extremely susceptible to HPV-induced cancers [8,9].
It is known that suppression influenced oncoproteins
E6 and E7 of HPV high-risk oncogenic gene expression
of interferon, interferon genes and IL-18 production,
which directly regulates the γ-interferonogenesis, as well
as increased production of immunosuppressive cytokines
that inhibit the development of T helper cells of Th1-
type and the production of interferon-γ and IL-2, which
is one of the most important evolutionary mechanisms
against HPV immune factors [9,18,19].
It is believed that another important co-factor in
HPV-induced neoplastic lesions is HSV infection
[8,25-30,37]. Therefore, we determined whether there is
a connection between the simultaneous infection of
HPV and HSV patients and changes in production of
pro- and anti-inflammatory cytokine ratio analysis
which allows to describe the direction of the immune
response toward predominant formation of cellular
(Th1 pathway) or humoral (Th2- pathway) reactions.
Assessment of cytokine production was performed by de-
termining their concentration in serum, since such studies
are widely used in laboratory practice to diagnose the state
of immunity. Therefore, we hypothesized that the results of
our study may have important diagnostic and predictive
clinical value, contributing to the predictive diagnosis of
herpetic infections in HPV-induced cervical precancerous
diseases, determining besides the presence of antibodies to
HSV-1 and HSV-2 in serum, the avidity of specific IgG
antibodies to these herpes virus. Determination of avidity ofspecific IgG is important for the diagnosis of various stages
of HSV infection and its development is characterized by
the presence of antibodies with different (low, medium or
high) avidity. We have previously shown [30] that in the
serum of patients with cervical precancerous conditions,
medium-avidity antibodies to HSV-1 and/or HSV-2 were
generally low.
In this study, we have shown that there is a relationship
between infection patients with cervical precancerous
conditions HPV and/or HSV-1 and HSV-2 suppression γ-
interferonogenesis. The important role is played by the de-
gree of avidity of IgG antibodies to HSV-1 and/or HSV-2.
In HPV-infected patients with low-avidity IgG antibodies
to HSV-1 and/or HSV-2, level of IFN-γ in serum was sig-
nificantly lower than in patients with medium-avidity IgG
antibodies to these herpes virus and in controls. HPV-
infected patients with low-avidity IgG antibodies to HSV-1
and/or HSV-2 often showed HPV oncogenic high and
medium risk oncoproteins E6 and E7 which are known to
suppress γ-interferonogenesis [9,18,19].
Previously, we have reported that in severe HPV-induced
cervical precancerous diseases, as CIN-II and CIN III, it
was observed that there is a more common incidence of
HPV-positive patients with low-avidity IgG antibodies to
HSV-1 and/or HSV-2 compared to the patients whose
blood serum contained medium-avidity IgG antibodies to
HSV-1 and/or HSV-2 [30]. In patients with CIN III, cancer
in situ, the production of IFN-γ was inhibited more clearly
than in CIN I and in benign cervical processes [15].
Whereas, among patients with cervical precancerous
diseases without herpetic infection in clinical form, the
IgM antibodies to HSV-1 and/or HSV-2 [30] were absent
in their serum; it is likely that the presence of low- and
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shows the final stage of primary HSV infection or exacer-
bation of a chronic process. Production of IFN-γ was
inhibited also in HPV-negative patients with cervical pre-
cancerous diseases of low- and medium-avidity IgG anti-
bodies to HSV-1 and/or HSV-2. Thus, the suppression of
γ-interferonogenesis may be due to both HPV infection as
HSV-1 and/or HSV-2.
Still, it is not clear whether infected patients with high-
or medium-risk HPV types lead to reactivation of HSV-1
or HSV-2 genome in the case of chronic process.
The analysis of our data may argue that HPV and HSV-1
or HSV-2 suppressing of γ-interferonogenesis may contrib-
ute to the development of HPV-induced cervical cancer,
since this cytokine is known [9] to control the progress and
growth of HPV-induced tumors.
We have previously shown that the HPV induced cer-
vical dysplasia in patients with decreased serum levels of
IFN-γ and IFN-α while increasing the levels of pro-
inflammatory cytokines, TNF-α and IL-1β, and cytokine
Th-2 type, IL-4 [9,15]. According to other authors in
HPV-induced warts, in the peripheral blood of patients,
there is also a decreased level of IFN-γ; the level of
TNF-α, IL-4 and IL-10 was significantly increased com-
pared with that of the controls [38].
In patients with cervical precancerous diseases with dif-
ferent avidity IgG antibodies to HSV-1 and/or HSV-2, we
have not observed the development of an active inflamma-
tory response, as the content of pro-inflammatory cyto-
kines like IFN-α, IL-1β, IL-2 and TNF-α maintained at
level of controls.
However, in HPV-infected and HPV-negative patients
with cervical precancerous disease with low- or medium-
avidity antibodies to HSV-1 or HSV-2, the concentration of
serum TGF-β 1 was significantly increased. It was reported
[21] that TGF-β1, contributing to chromosomal aberrations
of HPV-infected cervical epithelial cells, plays an important
role in the early stages of cervical carcinogenesis. However,
HPV-transformed cells themselves produce TGF-β1 and
certain other immunosuppressive cytokines, such as IL-10
[20]. TGF-β1 is a pleiotropic cytokine that can both inhibit
and stimulate cell proliferation, but tumor cells often lose
their sensitivity for cytokines [39]. Most researchers still
link the elevation of TGF-β1 production with increased
tumor growth [40-42]. It was found that the progression
of cervical intraepithelial neoplasia from mild to severe
stage correlates with increased TGF-β1 gene expression in
cervical samples (with smear scrape by Papanicolaou) [40].
Therefore, the increase of TGF-β1 production was reg-
istered in the present study in all compared groups,
which is probably the result of precancerous processes
of cervix than the result of HPV infection and/or HSV-1
and HSV-2 and therefore should be considered as un-
favorable predictive sign for these diseases.Thus, our findings showed that HPV-positive patients
with low-avidity IgG antibodies to HSV-1 and/or HSV-2
as well as HPV-negative patients with low- and medium-
avidity IgG antibodies to HSV-1 and/or HSV-2 showed
the violation of production of IFN-γ, confirming the im-
munosuppressive state. However, the level of TGF-β sig-
nificantly increased in the serum of HPV-positive as well
as HPV-negative patients of all groups.
While for HPV-negative patients with low-avidity IgG
antibodies to HSV-1 and/or HSV-2, the production of
IL-10 increased. The level of IL-10 in serum also in-
creased in HPV-positive patients with CIN III according
to other studies [16].
According to the literature data, the reduction of IFN-γ
and IL-2 and increased levels of IL-4 and IL-10 in serum
may be considered as a predictive biomarker for unfavor-
able prognosis in some forms of HPV-induced cancers as
a shift from Th-1 to Th-2 cytokines observed in metasta-
ses and in later stages of carcinogenesis [16,43].
Therefore, the presence of low-avidity IgG antibodies
to HSV-1 and/or HSV-2 in the serum of patients with
HPV-induced cervix precancerous diseases does not de-
pend on the reactivation of HSV genome (genital herpes
or generalized herpetic infection) which may be an indi-
cation for treatment as immunomodulators and antiviral
(antiherpetic) drugs.
Expert recommendations
HPV-positive patients with low-avidity IgG antibodies to
HSV-1 and/or HSV-2 in the serum showed the violation
of production of IFN-γ, confirming the immunosuppres-
sive state. Therefore, the presence of low-avidity IgG anti-
bodies to HSV-1 and/or HSV-2 in the serum of patients
with HPV-induced cervix precancerous diseases does not
depend on the reactivation of HSV genome (meaning it is
genital herpes or herpetic system process) which may be
an indication for treatment as immunomodulators and
antiviral (antiherpetic) drugs. The level of TGF-β signifi-
cantly increased in the serum of HPV-positive as well as
HPV-negative patients with low- and medium-avidity IgG
antibodies to HSV-1 and/or HSV-2. Ultrasound was used
for the diagnosis of cervical dysplasia, and it showed the
sensitivity 97.18%, specificity 83.33%, positive predictive
value 93.24%, and negative predictive value 92.59%.
Future outlooks and recommendations
Considering the limitations of the current research, more
studies on larger cohorts using extensive technological
platform with the translational research approach are re-
quired for the assessment of different constitutional types,
collateral diseases, etc. with biomarker specificity/sensitiv-
ity calculations to formulate valid panel aiming for imple-
mentation for PPPM in complex women health. We
suggest also the further studies regarding virus infections,
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tions and interactions with promising substances in nano-
scale (e.g., nanoceria, nanogold) for complex impact for
female health considering wide spectrum of comorbidities
and related pathologies to initiate comparative studies to
establish science-based treatment algorithms and update
screening programs. After approval, develop safe and ef-
fective person-related treatments beneficial for individual
outcomes.
PPPM approach in complex women health
Integrative women health care includes multimodal ap-
proach for gynaecologic pathology management with
PPPM paradigm including the assessment in the following:
breast [3], endometrial [4] precancers, etc. and collateral
diseases as endocrine, autoimmunity, neurological, includ-
ing neurodegenerative, vaccine-related disorders, pelvic
pain management [44] in a point of view of predictive
diagnosis for personalized treatment and tailored prevent-
ive measures.
Cancerogenesis
It was acknowledged that more than 15% of viral infec-
tions are able to cause cancer in humans [45,46]. Thus,
HPV infection is attributed to 80% of all human cancers
and was supposed to play a central role in the develop-
ment of breast cancer [47-49]. Thus, among persistent
HPV infection, one of about 15 genotypes of carcino-
genic human papillomavirus causes almost all cases [50].
Schiffman et al. [50] described four major steps in cer-
vical cancer development:
1. Infection of metaplastic epithelium at the cervical
transformation zone, viral persistence, progression of
persistently infected epithelium to cervical precancer
and invasion through the basement membrane of
the epithelium;
2. Infection is extremely common in young women in
their first decade of sexual activity;
3. Persistent infections and precancer, typically within
5 to 10 years, from less than 10% of new infections;
4. And finally, the invasive cancer that arises over
many years, even decades, in a minority of women
with precancer, with a peak or plateau in risk at
about 35 to 55 years of age.
Each genotype of HPV acts as an independent infec-
tion, with differing carcinogenic risks linked to evolu-
tionary species.
Obesity, diabetes, diet and lifestyle-related issues
Metabolic disturbances in obesity causes a number of dis-
eases, namely cardiovascular system, number of tumor
sites, including lung cancer, breast cancer, uterine andovarian cancer; in women, there is a violation of ovarian-
menstrual cycle, local and systemic immunity and dyslip-
idemia. The recent data, regarding women’s differential
responses to lifestyle changes, support another branch of
research with a gender nutrition emphasis within predict-
ive, preventive, and personalized medicine [51]. There
were illustrated extensive interrelations among virus ac-
tion, cellular oxidative stress, gene damage, multiple im-
mune pathways and proteomic changes in diabetes
mellitus, cancer and many chronic disorders development,
many of them were also related to HPV infection [52].
Expand the immunologic study
In immunology, the signal pathways are still not studied
for gynecology cancers, promising is the ability of group of
factors considered, namely, probiotics, which affect the
relevant Toll-like receptors (TLRs) that promote effective
immune response and the initiation of an effective im-
mune defence. Application of probiotics/immunobiotics
might be a promising and integrative personalized use.
Oxidative stress
Oxidative stress (OS) induced by reactive oxygen species
(ROS) is one of the main factors in cellular aging, and
many cellular disorders cause extensive damage to DNA
and also in mitochondria [45]. OS is an interesting pro-
moting factor in HPV-initiated carcinogenesis; however,
its role has received little attention in this regard. In in-
flammation, ROS and nitric oxide (NO), generated by in-
flammatory cells, play a key role in carcinogenesis. Thus,
ROS can induce the formation of 8-oxodG, an indicator of
oxidative DNA damage while NO can induce the forma-
tion of 8-nitroguanine, a marker of nitrative DNA damage.
These factors are potentially mutagenic, which may ac-
count for the cancer-promoting effect of inflammation. It
is reported that high-risk HPV types promote inducible
nitric oxide synthase-dependent DNA damage, which
leads to dysplastic changes and carcinogenesis [45]. While
therapeutic treatments cannot be based exclusively on the
abatement of oxidative stress, neutralizing this cellular dis-
order could minimize collateral damages associated with
the transformation of biomolecules in the cytosol.
Nanotechnologies - the challenge for advanced diagnosis,
treatment and prevention
Advances in nanoscience, nanotechnology and nanome-
dicine lead to the construction of new materials and de-
vices for various scientific and therapeutic purposes,
which are applicable in molecular diagnostics, nanodiag-
nostics, and improvements in the discovery, design and
delivery of drugs, including nanopharmaceuticals. The
application of nanoparticles allowing the combination
of therapy and diagnosis, known as theranostic, has
received increasing attention in biomedicine [53].
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pects of the application of nanoparticles in biomedical
purposes still remain poorly understood. While oxidative
stress has been postulated as one of the main physiopa-
thological hallmarks of most of chronic diseases, the
nanoparticles of gold [53,54] and cerium dioxide [55] were
reported as strong agents against oxidative damage, having
anti-aging activity. Nanoparticles of cerium dioxide con-
sidering its UV-shielding effect, antiviral, antibacterial and
antifungal activity, cardioprotective, neurotrophic, hepato-
and nephroprotective and anti-aging effect have potential
for various biomedical applications.
The mechanisms of antiviral activity of nanocrystal-
line cerium dioxide were reported [53] as a universal
nature action and can be directed to different targets in
a cycle of virus reproduction (Figure 8). The nanoceria
are able to hydrolyze ether-phosphate connections in
biological molecules and inhibit phosphorylation of IκB,
reducing the activity of NF-κB upon viral replication.
Thus, HSV activates IKK-kinase, while phosphorylation
of the inhibitory protein IκB causes transcriptional acti-
vation of nuclear factor NF-κB; in turn, NF-κB activation
increases the expression of the viral gene. Development
and introduction into clinical practice of drugs thatFigure 8 Alleged scheme of antiviral activity of nanocrystalline ceriuminhibit phosphorylation IκB will open a new direction in
the treatment of herpes infections (Figure 8).
If the virus is located near the nanoparticle with similar/
smaller size than virus, the interaction between the virus
and particle may occur due to fluctuating fields (the
analogue of van der Waals forces). Due to fluctuations of
the electromagnetic field, interaction between the nano-
particles with sufficiently large values of the non-linear
polar leads to capacity building, which causes attraction at
large distances, and at distances of the order of particle
sizes - repulsion.
The antiviral activity mechanisms of nanoceria that we
discovered are of particular interest and are for further
study because these open the prospect of using biosafe
and biocompatible nanoconstructions to perform benefi-
cial prevention and treatment of viral diseases for patients.
Treatment with nanoceria has supplementary perspectives
in gynecology and reproductive medicine as it results in the
increase in the number of oocytes in follicles, increase in the
number of oocytes at metaphase I and metaphase II, in-
crease in the number of living granulosa cells and decrease
in the number of necrotic and apoptotic cells [55].
Developing the technological platform for synthesis of
virus-like nanoparticles is promising for designing safe anddioxide against the herpes virus. CDN, cerium dioxide nanoparticles.
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anticancer theranostic application, it is a significant impact
in order to develop in PPPM in women health and repro-
ductive medicine. Nanosensors could be used for screening
the affinity between the identified proteins and the immuno-
logical synapses; protein arrays can be used to discover new
antigenic determinants for vaccine development.
HPV vaccines
Vaccines offer a safe and cost-effective prevention; on
the other hand, disappointing results of vaccine-related
disorders require the shift of the ‘risk curve’ in order to
better select cheap, efficacious and well-tolerated vaccine
candidates. Vaccines do not eliminate the risk of HPV-
induced cervical cancer; cervical screening programs will
still be required to minimize cancer incidence. Thus, to
develop innovative HPV vaccines and in order for the
vaccines to reach populations in greatest need, financing
mechanisms and multidisciplinary partnerships is essen-
tial [56,57]. The administration of HPV vaccine to HPV-
naive women (in schools), as well as to women who are
already sexually active to reduce the incidence of HPV16/
18-related cervical precancers and cervical cancer [57] is
discussed. The development of new successful personalized
treatment, prospective to promote effective immune re-
sponse to infectious and related diseases, depends on the
early detection of the etiological agent and any antibiotic
resistances in a point of view of individual predisposition.
Mathematical models
We suggest to follow up this study in regards to pro-
found assessment of all the panel of biomarker infor-
mation using advanced biostatistics and bioinformatics
techniques. We can suggest a mathematical model
that integrates those multiparameter data, according to
which the medical process is perceived as a complex
system like ‘black box’ [58,59] and can describe the
process (in particular, HPV-induced cancerogenesis) by
some of the primary indicators (panel of biomarkers).
So primary indicators and output rate are stochastic in
nature and presented as statistical information. Such
model may lead to integrate all biomarkers of the panels
to be applicable in real PPPM practice in the HPV-
induced cervical precancerous lesions.
Development of biomarkers panel
Several biologic markers or indexes have been studied as
potential tools to determine the prognosis and biological
behavior of cervical cancer [60]. It was suggested that
new HPV-oriented model of cervical carcinogenesis
should update and gradually replace older morphological
models based only on cytology and histology [50]. It can
be promising to develop biomarkers, fed through differ-
ent techniques, that are applicable to minimize theincidence of cervical cancer and the morbidity and mor-
tality it causes even in low-resource settings, leading to
improve prevention and clinical management strategies,
including improved screening tests and vaccines.
Phenotypic (at the tissue, cellular, and molecular levels)
and genotypic biomarkers are potential surrogate end
points for cancer incidence [61]. This would require that
both the phenotype and genotype of the target tissue in
agent-treated subjects, especially in any new or remaining
precancers, are equivalent to or show less progression
than those of the placebo-treated subjects.
Precancer (intraepithelial neoplasia) has been considered
the primary phenotypic surrogate end point. Promising are
the biomarkers measuring specific and general genotypic
changes correlating to the carcinogenesis (e.g., progressive
genomic instability as measured by loss of heterozygosity
or amplification at a specific microsatellite loci). Thus,
virus induce the activation of c-MYC protein suppressing
the cell cycle controlling activity of P53 and allows, there-
fore, the development of new tumorigenic phenotype of
transformed human cells. In consensus, the activated syn-
thesis of HPV proteins E6, E7, E1 and E2 has been shown
to be involved in the induction of malignant cell trans-
formation [45,48], a key interaction as regards to oncopro-
teins E6 and E7 of HPV types of high oncogenic risk of
intracellular factors that play an important role in the
regulation of growth, differentiation, and apoptosis.
Integration of HPV DNA of high oncogenic risk to the
host cell genome is undoubtedly a major factor in the per-
sistence of the virus and its carcinogenic potential. How-
ever, there was an obtained evidence of other risk factors
for HPVI and malignant transformation of HPV-infected
cells [10]. In particular, the important role of the immune
defence of the organism, especially cellular immunity and
cytokine production of Th1-type IFN-γ and IL-2, is to exe-
cute control over the viral infection and tumor growth [12].
HPV oncoproteins can evade immune surveillance of the
factors or even cause immunosuppression by manipulating
the immune mechanisms of the host cell. In addition, the
recently established oncoproteins E6 and E7 of HPV types
of high oncogenic risk inhibit gene expression of interferon
and interferon-induced genes and reduce the sensitivity of
cells to IFN. This is one of the most important mechanisms
of carcinogenic action [18] because the development and
nature of the viral diseases depend on the specific inter-
action of the virus-cell system where its leading role has dif-
ferent types of interferon. Therefore, violation of interferon
production may underlie relapse HPVI and be a risk factor
for the development of HPV-induced malignant tumors.
Biomarkers of immunosuppression may be considered
as follows [8,9,38]: the levels of various cytokines, namely
IFN-γ, IL-2 and IL-12; cytotoxic T-lymphocyte antigen 4
(CD4), glucocorticoid-induced tumor necrosis factor re-
ceptor (TNFR)-related protein and programd cell death
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cated on the surface of NK), namely levels of NKG2D and
NKp46 and the expression levels of tumor necrosis factor-
α, IL-4 and IL-10. Increased expression of MyD88 and
TLRs is likely to enhance immunosuppression of Tregs,
leading to the imbalance of Th1/Th2 and cytotoxic T cell
type 1 (Tc1)/Tc2 cells. Our results illustrated that the pres-
ence of low-avidity IgG antibodies to HSV-1 and/or HSV-
2 is the biomarker of immunosuppressive state.
Other potential surrogate end points that may occur
earlier in carcinogenesis may include proliferation and
differentiation indices, specific gene and general chromo-
some damage, cell growth regulatory molecules and bio-
chemical activities (e.g., enzyme inhibition); Ki67, a
nuclear proliferation associated antigen is expressed in
the growth and synthesis phases of the cell cycle (G1, S,
G2 and mitosis). Serum biomarkers also may be moni-
tored because of their accessibility [61].
The expression patterns of three potential dysplastic
biomarkers, p16INK4A, CDC6, and MCM5, was discussed
and compared in [62] to evaluate their use as predictive
biomarkers in squamous and glandular cervical preinva-
sive neoplasia. Combinations of biomarkers may be useful
in difficult diagnostic cases. Thus, p16INK4A expression is
closely associated with high-risk HPV infection; MCM5
staining intensity is independent of high-risk HPV infec-
tion, highlighting its potential as a biomarker in both HPV
dependent and independent cervical dysplasia, and CDC6
may be a biomarker of high-grade and invasive lesions of
the cervix, with limited use in low-grade dysplasia. Thus,
p16INK4A may be suggested as the most reliable marker of
cervical dysplasia among dysplastic group [62].
Current data support the association of oral contraceptive
use with cervical adenocarcinomas in situ; however, no
other evidence was found that oral contraceptives inde-
pendently increase the risk of cervical carcinomas [63].
The insulin-like growth factor (IGF) system is organized
in a complex regulatory network at the cellular and sub-
cellular levels. The IGF system has a key physiological role
in the development of the organism and maintenance of
normal cellular function during fetal and postnatal life and
plays a central role in many aspects of the development
and progression of cervical cancer. The IGF system con-
sists of three ligands, IGF-I, IGF-II and insulin; three cell
membrane receptors, IGF-I receptor (IGF-IR), insulin re-
ceptor (IR) and IGF-II receptor (IGF-IIR); and six high-
affinity IGF binding proteins, IGFBP − 1 through −6, their
specific proteases (IGFBP proteases) and membrane re-
ceptors (IGFBP-R). IGF-I is a potent mitogenic growth
factor that plays a critical role in cancergenesis [64].
Hormones
Immunohistochemistry (IHC) is probably the most afford-
able and simple technology to detect many biomarkers[60]. The differences in immunohistochemical expression
of p53, bcl-2, bax, estrogen receptor (ER), and progester-
one receptor (PR), androgen receptor (AR), progesterone
receptor antagonists (PA), etc. should be properly assessed
to find the most common diagnostic pitfalls and helpful
morphologic and immunohistochemical markers [4].
Oncomarkers
Elevated CA 125 levels are detectable in 20% to 75% of
patients with cervical adenocarcinoma and have been as-
sociated with advanced tumor stage, large tumor size,
high histological grade, lymph node involvement and
status [64].
Vieira et al. [65] proposed anti-CD34 as a marker for
evaluating angiogenesis in cervical cancer [66]. Anti-CD34
antibody is a highly sensitive marker for endothelial cell
differentiation and has also been studied as a marker for
vascular tumors [67]. A recent study supports the power
of serum markers such as squamous cell carcinoma anti-
gen (SCC), CYFRA 21–1, CA 125, immunosuppressive
acidic protein (IAP) and vascular endothelial growth factor
(VEGF) in patients with cervical cancer [65].
Proteomics
Proteomics is a powerful tool for the development of mo-
lecular biomarkers in the postgenomic era and provides
the hope of discovering novel biological markers for use in
the screening, early diagnosis and prediction of response
to therapy [68]. Proteomics strategies are powerful enough
to identify novel co-carcinogenic factors and to under-
stand the mechanisms of tumor development, interplay
between viral infection and protein dysfunction, consider-
ing selective interaction of viral oncogenes with a subset
of intracellular proteins mainly involved in apoptosis re-
sistance, cell growth and differentiation and cell trans-
formation [69].
Proteomic studies of membrane proteins are an analyt-
ical challenge due to their dynamic physicochemical
characteristics, hydrophobicity and heterogeneity. Differ-
ences in the membrane proteomes of two cervical cancer
cell lines may correlate with the invasive potential [70].
The results of studies on membrane proteomes of cer-
vical cancer cell lines, differing in viral status and inva-
sive phenotypes are the following: HeLa, an invasive
HPV positive cell line, and C33-A, a non-invasive HPV
negative cell line [70]. Metastasis is the most common
cause of mortality in cervical cancer. Key molecular ele-
ments of the plasma membrane and cytoskeleton are re-
sponsible for cell motility and invasion.
Human papillomavirus oncogenic proteins E6 and E7
were suggested to target the p53 and Rb pathways; E6
can enhance telomerase activity, whereas E7 inhibits a
p16ink4A-dependent pathway that limits cellular prolife-
ration in epithelial cells [71]. Thus, HPV oncogenes
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accumulating genomic alteration, thus ultimately leading
to the full neoplastic state. HPV E6 and E7 oncoproteins
allow for the accumulation of genetic mutations and the
survival of mutated cells, their expression also contrib-
utes to the immortalization of infected cells [72]. Only a
minor percentage of viral infections lead to invasive growth,
thereby indicating insufficient role of viral oncogene ex-
pression that could be either related to a long-term viral
protein expression or the results of many co-factor(s),
namely, viral and non-viral; host, and environmental factors
should be investigated [6,7,73], including the role of
pro- and anti-inflammatory cytokines presented in the
current study.
Cervical mucous or cervical vaginal fluid (CVF) is po-
tentially an ideal sample to screen for biomarkers for
early detection of cervical cancer. A recent study identi-
fied 151 new proteins that included proteins present in
the lower female genital tract, such as HBD-2 and cathe-
licidin, two proteins that play an important role in the
innate cervicovaginal immunity [74].
Imaging (US, MRI, PET-CT)
Magnetic resonance imaging (MRI) is the most effective
technique to assess the type, degree of differentiation,
presence or absence of lymphovascular invasion, lymph
node involvement, etc. Magnetic resonance spectroscopy
(MRS) may support additional characteristics, namely
ADC and total choline, that may be suggested in a role
of predictive biomarkers. Thus, ADC coefficients were
reported to be lower in cancer compared to normal cer-
vical tissue, with degree of tumor differentiation contrib-
uting to this difference [75]. Baseline ADC and focal
regions of ADC restriction predict for partial response
with moderate sensitivity and specificity in patients with
postoperative recurrences of cervical cancer and need to
be validated in larger cohort. Chopra et al. investigated
diffusion-weighted MR imaging (DWI) as a response
biomarker in patients undergoing chemoradiation for
postoperative recurrences of cervical cancer [76].
Positron emission tomography-computed tomography
(PET-CT) has higher sensitivity and specificity than do
conventional anatomic modalities and is valuable in de-
termining the extent of disease and detecting recurrent
or residual tumor [77]. In locally advanced cervical
cancer, 18F-fluorodeoxyglucose (FDG) positron emis-
sion tomography-computed tomography (PET/CT) has
become important in the initial evaluation of disease
extent. 64Cu-labelled diacetyl-di(N(4)-methylthiosemi-
carbazone) is taken up by hypoxic tissues, which may
be valuable for prognostication and radiation treat-
ment planning [78]. However, Schöder et al. discuss
the potential financial, legal and radiation safety impli-
cations associated with using whole-body PET/CT forcancer screening, diagnosing, staging and restaging cancer
and for monitoring treatment effects. In spite of advocat-
ing CT, PET or PET/CT for whole-body screening, recom-
mendations and decisions regarding cancer screening
should be based on reliable data, not good intention, as-
sumptions or speculation [74]. For these reasons, actually,
we still cannot consider PET as a perspective screening tool
for cervical cancer.Elastography - promising non-invasive biomarker
Schöder and Gönen [79] investigated elastography of the
uterine cervix in non-pregnant women and showed that
there was no correlation between cervical stiffness and pa-
tient age, but Thomas et al. found that it was possible to
diagnose malignant tumors of the cervix using this
method [80]. Authors hypothesize that the directionality
of the tissue mechanical response is primarily due to pref-
erential collagen orientation in the cervical stroma, sug-
gesting that cervical tissue is mechanically anisotropic
with a uniaxial response dependent on the direction of
loading, the anatomical site of the specimen and the ob-
stetric history of the patient [80]. Differences between the
soft internal os and harder external parts of the cervix are
good predictors of a favorable reaction to oxytocin during
induction of labor [81].
Dopplerography of the cervix revealed significant dif-
ferences in all existing indices studied between women
with cervical precancerous lesions or cancer and healthy
women. In women with cervical cancer, an advanced
stage is associated with higher velocity indices [82,83].
High vascularity has been known as a characteristic of
grade 3 CIN and invasive lesions; angiogenesis has been
associated as indicator of prognosis. There is a study
demonstrating that microvessel density in carcinomas of
the uterine cervix is a factor associated with poor progno-
sis [84]. Pelvic congestion and vascular redistribution are
involved to the pathogenesis of being a promising sup-
porter for imaging and lab biomarkers. Peripheral micro-
circulation assessment might be considered to support a
supplementary information for cervical cancer patients
[85]. Laboratory biomarkers representing vascularization
may be conjoined with imaging data [66,67] in particular
for vasospasm assessment.
The most specific colposcopic signs of PVI are aceto-
white epithelium, positive iodine punctuation and mo-
saic, and atypical transformation zone [9].
Numeral challenges for optical imaging optimization
were suggested, e.g., enhancing techniques with use of
quantum dots that provide a promising alternative to
conventional organic dyes for biological imaging, that
when combined with optical imaging technologies can
help visualize malignant changes in cervix at the mo-
lecular level [86].
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proved and potential) for cervical carcinogenesis based on
the currently available HPV-oriented model, leading to
improve prevention and clinical management strategies,
including improved screening tests and vaccines, reliably
diagnosing that can help in the choice of multiple thera-
peutic alternatives most likely to benefit the patients [66],
and to minimize the incidence of cervical cancer and its
morbidity and mortality, even in low-cost settings.
Panel of biomarkers
The following are the panel of biomarkers:
1. Phenotypic (at the tissue, cellular, and molecular levels)
 Proteomic biomarkers (proteins of enzymes,
growth factors, cell adhesion molecules, calcium-
binding proteins, proteases, protease inhibitors,
transporter proteins, structural molecules,
apoptosis inhibitor, molecular chaperone, as well
as proteins related to cell growth, cell differentiation,
cell transformation, tumor invasion, carcinogen
metabolism, etc.) [87];
 Serum biomarkers of proliferation and
differentiation (growth regulatory molecules, and
biochemical activities (e.g., enzyme inhibition);
Ki67, a nuclear proliferation associated antigen);
 The histological biomarkers of cervical HPVI:
exophytic and typical flat warts, mild changes of
plane and metaplastic epithelium (single
koilocytes) condylomatosis cervicitis, CIN of
varying grades with/without koilocytes, and
cervical cancer [9];
 Dysplastic biomarkers: p16INK4A, CDC6 and
MCM5 [56];
 Viral biomarkers: virus herpes, HPV-related
biomarkers (viral proteins E6, E7, E1 and E2, etc.);
 Receptors (ER) and PR, AR, PA);
 The insulin-like growth factor (IGF) system
receptors (IR, IGF-IR, IGF-IR/IR hybrids and
IGF-IIR), the peptides (IGF-I, IGF-II and insulin),
six high affinity IGFBPs (−1 to −6), IGFBP
proteases and IGFBP receptors (IGFBP-R);
 Cancer antigen (biomolecules) based biomarkers:
cancer antigen 125 (CA125);
 Receptors of the diffuse neuroendocrine system
(amine precursor uptake and decarboxylase,
APUD cells);
 Apoptosis biomarkers (Ki67, etc.);
 CVF samples for HBD-2 and cathelicidin testing;
 Oxidative stress biomarkers: DNA oxidation
biomarkers (oxidized DNA bases such as
8-OHdG, autoantibodies to oxidized DNA,
modified comet assay), lipid oxidation
(thiobarbituric acid-reactive substances, exhaledpentane/ethane, low-density lipoprotein resistance
to oxidation, isoprostanes), protein oxidation
(protein carbonyls) [45,88];
 Nitrosative stress biomarkers: NO, nitrite,
peroxynitrite, and inducible NO synthase (iNOS)
expression, modificated proteins, nitrosothiols,
8-nitroguanine (a marker of nitrative DNA
damage), etc. [45,89,90];
 Vasospasm biomarkers (endothelin, NO, etc.)
[91,92].
2. Genotypic biomarkers (oncogenic types of HPV,
c-MYC protein system, activity of P53, bcl-2, bax,
TFPI2, Secreted Protein Acidic and Rich in Cysteine
(SPARC) [93,94],etc.).
3. Immunological biomarkers Biomarkers of immunosuppression:
immunosuppressive acidic protein (IAP);
low-avidity IgG antibodies to HSV in HPV-
positive patients leading violation of production
of IFN-γ; various cytokines in the peripheral
blood that IL-2, IL-12 and interferon-γ; cytotoxic
T-lymphocyte antigen 4, glucocorticoid-
induced TNFR-related protein and programd
cell death protein 1 [38]; NK cells biomarkers
(levels of NKG2D and NKp46, natural killer
(NK) cell activation receptors located on the
surface of NK); the expression levels of tumor
necrosis factor-α, IL-4 and IL-10; expression
of MyD88 and TLRs is likely to enhance
immunosuppression of Tregs, leading to the
imbalance of Th1/Th2, cytotoxic T cell type 1
(Tc1)/Tc2 cells.4. Imaging biomarkers
 MR imaging/MR sprectroscopy: metabolic
biomarkers, diffusion-weighted imaging, etc.;
 Ultrasound (conventional, dopplerography;
sonoelastography, performed in specific
phases of cycle; nabotian cysts; cervicosis,
polyps; hydrocerix; stiff cervical lesions,
fibrosis; pelvic congestion, ovulation
assessment);
 PET-CT (has rather poor screening value);
 Colposcopy: specific colposcopic signs of PVI
are acetowhite epithelium, positive iodine
punctuation and mosaic, atypical
transformation zone [9], develop in vivo
subcellular imaging, enhancing optical imaging
techniques as quantum dots [64];
 Pathology, immunohistochemistry
(immunohistochemical expression of p53,
bcl-2, bax, ER, and PR, AR, PA, etc.);
 Cellular, subcellular imaging.
5. Biomarkers in pregnant women [95];
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(cancer, diabetes, infections, etc.), HPV infection and
sexual history data from properly constructed
questionnaires, and cytological screening [57].
Education for preventive measures
Educational programs and individual preventive facilities
for sexually active persons are important tasks for PPPM.
The material for dissemination and lecturing should be
standardized (well translated, to be easily understood) in
order to facilitate the work. Disseminate information and
perform campaign for organization of free health check
up available in low cost (ultrasound, cytological screening,
most valid biomarkers) and vaccination in childhood, es-
pecially in developing countries, and in time implementa-
tion of novel scientific findings in the field. Support
preventive educational activity with long-term commit-
ment of private and public funding programs.
Potential economical benefits of PPPM
Cancer of the cervix accounts for over 60% of the
gynecological cancer burden in developing countries
which causes about 500,000 new cases and 250,000
deaths each year [5], despite being preventable by
current technologies. The portions of the total costs of
cancer have been estimated to be as high as US$895
billion worldwide [96]. The cost of new gynecological
cancers in developing countries in 2009 totalled US$1,087
million compared to the US$11.9 billion spent in devel-
oped countries; in 2009, cancer burden in EU were esti-
mated as 126 billion €, in particular for cervix uteri
which is 2,664 million € [97].
The impact of HPV is not just clinical. The evaluation and
treatment of the clinical manifestations of HPV also have an
enormous monetary impact on the health care system [98].
The economic burden that was associated with non-cervical
HPV-6, 11, 16, and 18-related conditions in the US popula-
tion in the year 2003 approximates US$418 million (range,
US$160 million to US$1.6 billion) [99]. Thus, HPV testing
requires more high-technology laboratory-based molecular
analyses, involving higher costs. A primary HPV detection
test for a routine screening with a higher sensitivity and
negative predictive value for the detection of preinvasive dis-
ease than cytology, and being in low cost is called to be de-
veloped [96]. Many HPV-related diseases namely diabetes
and cancer might be considered for integrative preventions
within virus, immunology and genetics chain that should
benefit the indirect economical effects [100].
Consolidation of the PPPM concept
Thus, our analysis of assessment of biomarker panel in-
cluding current research of pro- and anti-inflammatory
cytokines in patients with papillomavirus and herpes
simplex virus infections allows to conclude as follows:Personalized medical approach
Each individual pathological pattern of the production of
pro- and anti-inflammatory cytokines in HPV-induced
cervical precancerous diseases in patients infected with
HSV1 and/or HSV2 in serum IgG, identified with vary-
ing degrees of avidity, specific to these herpes virus are
promising biomarkers that defines further personalized
tactics of comprehensive treatment using immunomodu-
lators and antiviral drugs. The combination of diagnostic
modalities such as imaging, serum and CVF biomarkers
should help in the choice of multiple therapeutic alter-
natives as currently available integrative treatment (sur-
gery, cryotherapy, radiotherapy, chemotherapy, etc.) that
is beneficial to the patients.
Predictive medical approach
Assessment of extensive biomarkers panel for cervical car-
cinogenesis based on HPV-oriented model should minimize
the incidence of cervical cancer, and the morbidity and
mortality it causes, even in low-cost settings, leading to im-
proved prevention and clinical management strategies, in-
cluding improved screening tests and vaccines. Persistent
herpes virus, HPV infections have a high-risk for deve-
lopment of a number of collateral/infection-induced chro-
nic diseases, namely cancer, cardiovascular, endocrine,
autoimmune, metabolic, neurological diseases, that re-
quire research programs to support high levels of scien-
tific and technological development for novel predictive
programs. Levels of pro- and anti-inflammatory cyto-
kines in papillomavirus and herpes simplex virus infec-
tions in patients have strong predictive value which
has potential for development of predictive biomarkers
for personalized treatment and tailored prevention of
cervical precancerous lesions. Possibly, an imbalance of
cytokine production Th1, 2, 3-type and anti-inflammatory
cytokines may underlie CC relapse in HPVI and be a risk
factor for HPV-induced malignancies. Expand biomarkers
panel and proceed in the validation of new biomarkers in
the shortest terms.Preventive medical approach
Our results may lead to initiate the programs for women
at risk to prevent cervical cancer and improve quality of
life. In parallel with extensive biomarker panel develop
preventive programs adapted for developing countries,
namely campaigns for vaccination at schools, suggesting
valid and simple diagnostic tests with self sampling and
treatment with basic medicines. It is recommended to
promote programs for introduction of ambulatory (‘office’)
integrative women health care to a new level of efficiency
and safety of the method.
With the concluding points, we can formulate the fol-
lowing proposals (expert recommendations):
Lazarenko et al. The EPMA Journal 2014, 5:1 Page 17 of 20
http://www.epmajournal.com/content/5/1/11. For the European Union (EU): create an international
research project to study integrative diagnosis and
treatment towards women health improvement with
regards to preserve the reproductive function.
Perform sufficient evidence studies to determine
relationships in virus, genetics, immune pathways,
receptor system, to expand biomarkers panel that will
allow and develop novel treatments and to
complement the diagnostic algorithm.
2. For Ukraine: it is recommended to promote
programs of routine screening of preinvasive disease
with HPV and HSV detection and assessment
immunity status; introduction of personalized
outpatient gynecological care with high level of
efficiency and patient safety; the introduction of
ambulatory (‘office’) care as the patient-centered
medical home (PCMH) model for health care delivery;
to participate in project and in partnership with EU to
follow up experimental and clinical trials and involve
related institutions and centers to the study.
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